Fund Holdings — Propel Bio Management, LLC

Total Portfolio Value:
$117.12M
Total Bought:
$36.77M
Total Sold:
$28.17M
Net Transaction:
+$8.60M
Notable People:
Leen Kawas, James Francis Harding
Securities
▲▼
SharesValue
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Plains GP Holdings, L.P.LTD PARTNR INT A(PAGP)1,272,3601,272,3600$23.21M$24.35M20.79%+$1.15M
Achieve Life Sciences Inc3,786,4253,786,4250$11.93M$18.82M16.07%+$6.89M
Phathom Pharmaceuticals, Inc.(PHAT)552,927740,918+187,991$6.51M$12.29M10.49%+$5.78M
Viridian Therapeutics, Inc.(VRDN)90,000282,531+192,531$1.94M$8.79M7.51%+$6.85M
Milestone Pharmaceuticals Inc.(MIST)5,124,8904,118,321-1,006,569$10.25M$8.32M7.10%-$1.93M
Kyverna Therapeutics, Inc.(KYTX)0666,666+666,666$0$6.27M5.35%+$6.27M
COMPASS Pathways plcADS(CMPS)510,000861,778+351,778$2.92M$5.95M5.08%+$3.02M
Inventiva S.A.ADS(IVA)01,000,000+1,000,000$0$4.65M3.97%+$4.65M
Delcath Systems, Inc.(DCTH)438,509438,5090$4.71M$4.43M3.78%-$285.0K
Abeona Therapeutics Inc.(ABEO)974,022830,780-143,242$5.14M$4.38M3.74%-$764.6K
Celldex Therapeutics, Inc.(CLDX)155,000154,300-700$4.01M$4.19M3.58%+$180.9K
Nektar Therapeutics(NKTR)49,00082,822+33,822$2.79M$3.50M2.99%+$713.6K
Oculis Holding AG(OCS)0172,839+172,839$0$3.45M2.95%+$3.45M
SAB Biotherapeutics, Inc.(SABS)0652,881+652,881$0$2.44M2.08%+$2.44M
REGENXBIO Inc.(RGNX)0116,896+116,896$0$1.68M1.44%+$1.68M
LeonaBio, Inc.(LONA)149,279149,2790$618.0K$1.13M0.96%+$512.0K
LENZ Therapeutics, Inc.(LENZ)059,085+59,085$0$945.4K0.81%+$945.4K
Aardvark Therapeutics Inc046,408+46,408$0$609.1K0.52%+$609.1K
Zevra Therapeutics, Inc.(ZVRA)231,87463,683-168,191$2.21M$570.6K0.49%-$1.63M
Kalaris Therapeutics, Inc.(KLRS)042,053+42,053$0$354.9K0.30%+$354.9K
Akero Therapeutics Inc228,8840-228,884$10.87M$0—-$10.87M
Applied Therapeutics Inc11,285,4200-11,285,420$6.83M$0—-$6.83M
Jasper Therapeutics, Inc.(JSPR)1,028,8060-1,028,806$2.45M$0—-$2.45M
TScan Therapeutics, Inc.(TCRX)1,932,3040-1,932,304$3.52M$0—-$3.52M
Page 1 of 1
Propel Bio Management, LLC — 13F Holdings — Q4 2025 | TickerTrail